Early Esophageal Cancer And Pre-cancer Eliminated With Non-surgical Treatment Combination

SUNNYVALE, California -- BARRX Medical, Inc., a global technology leader in treating Barrett's esophagus, today announced the publication of two related European trials which report a 100% eradication rate for early esophageal cancer and pre-cancerous dysplasia using endoscopic resection followed by ablation therapy with the HALO ablation system. Barrett's esophagus is a complication of gastroesophageal reflux disease (GERD) and is a known risk factor for esophageal cancer, the fastest growing cancer in the Western world. Results of the two studies were published in the May issue of Endoscopy, a medical journal for gastroenterologists performing advanced endoscopic procedures. They were titled "Effective treatment of ear...